An independent data coordinating centre randomly allocated patients in a 2: 1 ratio to receive CDCs or standard care. For patients assigned to receive CDCs, autologous cells grown from endomyocardial biopsy specimens were infused into the infarct-related artery 1.5-3 months after myocardial infarction. The primary endpoint was proportion of patients at 6 months who died due to ventricular tachycardia,

ventricular fibrillation, or sudden unexpected death, or had myocardial infarction after cell infusion, new cardiac tumour formation on MRI, or a major adverse cardiac event (MACE; composite of death and hospital admission for heart failure or non-fatal recurrent myocardial infarction). We also assessed preliminary efficacy endpoints on MRI by 6 months. Data analysers were masked to group assignment. This study is registered with ClinicalTrials.gov, NCT00893360.

Findings Between Ispinesib chemical structure Nocodazole molecular weight May 5, 2009, and Dec 16, 2010, we randomly

allocated 31 eligible participants of whom 25 were included in a per-protocol analysis (17 to CDC group and eight to standard of care). Mean baseline left ventricular ejection fraction (LVEF) was 39% (SD 12) and scar occupied 24% (10) of left ventricular mass. Biopsy samples yielded prescribed cell doses within 36 days (SD 6). No complications were reported within 24 h of CDC infusion. By 6 months, no patients had died, developed cardiac tumours, or MACE in either group. Four patients (24%) in the CDC group had serious adverse events compared with one control (13%; p=1.00). Compared with controls at 6 months, MRI analysis of patients treated with CDCs

showed reductions in scar mass (p=0.001), increases in viable heart Necrostatin-1 chemical structure mass (p=0.01) and regional contractility (p=0.02), and regional systolic wall thickening (p=0.015). However, changes in end-diastolic volume, end-systolic volume, and LVEF did not differ between groups by 6 months.

Interpretation We show intracoronary infusion of autologous CDCs after myocardial infarction is safe, warranting the expansion of such therapy to phase 2 study. The unprecedented increases we noted in viable myocardium, which are consistent with therapeutic regeneration, merit further assessment of clinical outcomes.”
“The influence of dietary fatty acids (I-As) other than omega-3 FAs on mood has been largely overlooked. The authors prospectively assessed the association between dietary linoleic and oleic FAs and the risk of severe depressed mood (SDM) among 4856 adults aged 25-74 years who were examined in 1971-1975 as a part of a national survey. intakes of FAs were obtained at baseline from a 24-hour recall and categorized into thirds. SDM was defined as Center for Epidemiologic Studies Depression Scale scores at follow-up survey >= 22 or taking anti-depression medication. After an average of 10.